The European Commission sent Teva a statement of objections for artificially extending patent protection for its Copaxone medicine and spreading misleading information for the rival MS medicine to prevent its market entry. The press release dated 10 October 2022 is available via https://ec.europa.eu/commission/presscorner/detail/en/ip_22_6062